In a cohort of 62 post-operative patients with pancreatic cancer treated with adjuvant gemcitabine, ANXA2 was overexpressed in tumour tissue and the level of expression significantly correlated with rapid recurrence, demonstrating ANXA2 as an independent prognostic indicator for shortened disease-free and overall survival [172]. This evidence concerns the gene ANXA2 and familial pancreatic carcinoma.